Richard Hollis, Chairman, President and CEO of Hollis-Eden Pharmaceuticals Talks to The Wall Street Transcript
November 17 2008 - 9:28AM
Business Wire
The Wall Street Transcript has published an in-depth interview with
Richard Hollis, Chairman, President and CEO of Hollis-Eden
Pharmaceuticals (NASDAQ:HEPH) in which he talks at length about the
Company. The entire 2,500 word interview is available free online
at http://www.twst.com/ceos.htm Hollis-Eden Pharmaceuticals, Inc.
is a world leader in the development of a proprietary class of
adrenal steroid hormones as novel pharmaceuticals for human health.
The Company�s clinical drug development candidates include TRIOLEX�
(HE3286), a next-generation compound currently in clinical trials
for the treatment of type 2 diabetes, ulcerative colitis and
rheumatoid arthritis, and APOPTONE� (HE3235), a next-generation
compound in a clinical trial for late-stage prostate cancer. In
addition to these clinical development candidates, Hollis-Eden has
an active research program that is generating additional new
clinical leads that are being further evaluated in preclinical
models of a number of different diseases. When asked about the
company�s product candidates Mr. Hollis stated, �We�ve discovered
novel innovative first-in-class drug candidates that are based on
endogenous adrenal steroid hormones, and since these are nature�s
products, they are basically designed to perform certain functions
that can be used in treating human diseases. So I believe the
probability of translation from pre-clinical animal models to
humans should be very high because the products originate out of
our own metabolome.� Regarding the company's clinical studies Mr.
Hollis stated, �Clinical endpoint data is due over the next three
to six months and any inflection points that show that our
technology is safe and efficacious in those indications should also
allow us to expand into several other additional indications, which
would increase our economic opportunity even more.� The Wall Street
Transcript does not endorse the views of any interviewees nor does
it make stock recommendations. For subscription information call
800/246-7673.
Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
Historical Stock Chart
From Oct 2023 to Oct 2024